EUVIMEDEUVIMED entdecken
Open Access

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies

Daniel Wang iD, Caroline E Porter iD, Bora Lim iD, Amanda Rosewell Shaw iD, Catherine S Robertson, Mae L Woods iD, Ya Xu iD, Greyson G W Biegert iD, Daisuke Morita, Tao Wang iD, Bambi J Grilley, Helen Heslop iD und 2 weitere

Science Advances · 2023

DOI: 10.1126/sciadv.ade6790 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Daniel Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We show that a binary oncolytic/helper-dependent adenovirus (CAdVEC) that both lyses tumor cells and locally expresses the proinflammatory cytokine IL-12 and PD-L1 blocking antibody has potent antitumor activity in humanized mouse models. On the basis of these preclinical studies, we treated four patients with a single intratumoral injection of an ultralow dose of CAdVEC (NCT03740256), representing a dose of oncolytic adenovirus more than 100-fold lower than used in previous trials. While CAdVEC caused no significant toxicities, it repolarized the tumor microenvironment with increased infiltration of CD8 T cells. A single administration of CAdVEC was associated with both locoregional and abscopal effects on metastases and, in combination with systemic administration of immune checkpoint antibodies, induced sustained antitumor responses, including one complete and two partial responses. Hence, in both preclinical and clinical studies, CAdVEC is safe and even at extremely low doses is sufficiently potent to induce significant tumor control through oncolysis and immune repolarization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsMiceAnimalsAdenoviridaeCytokinesCell Line, TumorTumor Microenvironment

Substanzen

Cytokines

Autor:innen und Institutionen

  • Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA.
  • Duncan Cancer Center-Breast, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
  • Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

ORCID-Profile: Daniel Wang, Caroline E Porter, Bora Lim, Amanda Rosewell Shaw, Mae L Woods, Ya Xu, Greyson G W Biegert, Tao Wang, Helen Heslop, Malcolm K Brenner, Masataka Suzuki

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Wang, D., Porter, C. E., Lim, B., Rosewell Shaw, A., Robertson, C. S., Woods, M. L., Xu, Y., Biegert, G. G. W., Morita, D., Wang, T., Grilley, B. J., Heslop, H., Brenner, M. K., & Suzuki, M. (2023). Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advances. https://doi.org/10.1126/sciadv.ade6790

Vancouver

Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, et al. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Science Advances. 2023. doi:10.1126/sciadv.ade6790

BibTeX
@article{Wang2023,
  author = {Wang, Daniel and Porter, Caroline E and Lim, Bora and Rosewell Shaw, Amanda and Robertson, Catherine S and Woods, Mae L and Xu, Ya and Biegert, Greyson G W and Morita, Daisuke and Wang, Tao and Grilley, Bambi J and Heslop, Helen and Brenner, Malcolm K and Suzuki, Masataka},
  title = {Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.ade6790}
}
Kostenlos starten →